According to ME News, on July 23 (UTC+8), Nasdaq-listed Canton Strategic Holdings, Inc. (ticker: CNTN) announced that it has sold its biotechnology research division, Gravitas Life Sciences, LLC, to Gravitas Collective Corp. The transaction received unanimous approval from the board and was completed on July 17, 2026. The company stated that this transaction marks a significant milestone in its transformation into an operating company, with future plans to drive the digitization of traditional financial markets through Canton Network. Canton Strategic Holdings (formerly Tharimmune) supports Canton Network via Canton Coin and is also a strategic investor in the Canton ecosystem. (Source: Foresight News)
Canton Strategic Sells Biotech Subsidiary to Focus on Digital Finance
KuCoinFlashShare
Summary
On July 23 (UTC+8), NASDAQ-listed Canton Strategic Holdings (CNTN) announced the sale of its biotech R&D unit, Gravitas Life Sciences, to Gravitas Collective Corp. The transaction, approved by the board and finalized on July 17, 2026, supports the company’s strategic shift toward digital finance through the Canton Network. On-chain data reveals increasing interest in altcoins to watch as traditional markets embrace tokenization.
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.